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See Articles, pages 474–481 and pages 482–489AKI is a new name/concept of acute renal failure (ARF) proposed
by a group of scientiﬁc societies (AKI network), which is being
widely accepted by critical care and nephrology physicians [1].
It is based mainly on studies correlating changes in serum creat-
inine vs. morbidity and mortality in ICU patients. The term AKI
therefore deﬁnes an abrupt decrease in kidney function. AKI def-
inition modiﬁes two traditional paradigms of ARF. First, the rele-
vance of differentiating functional (prerenal) ARF from acute
tubular necrosis disappears with the AKI concept. This differenti-
ation is difﬁcult and correlates poorly with renal histology, clini-
cal features, and prognosis. Second, whereas a marked increase in
serum creatinine was required for the diagnosis of ARF in the
past, a small increase in serum creatinine (P0.3 mg/dl or P50%
over baseline) is required for the diagnosis of AKI. AKI may be
graded into three stages according to the magnitude of increase
in serum creatinine: Stage 1: 150–200%; Stage 2: >200–300%;
Stage 3: >300% or of at least 0.5 mg/dl in patients with baseline
serum creatinine ofP4 mg/dl or renal replacement therapy. Mor-
bidity and mortality increase in parallel with the AKI stages (no
AKI to AKI-3).
Despite the fact that the AKI concept has been elaborated
mainly for ICU patients, there is a movement to extend the AKI
concept to patients with decompensated cirrhosis. This editorial
discusses the traditional criteria used in the diagnosis of renal
failure in cirrhosis, the evidence currently available supporting
a change to the AKI criteria and, ﬁnally, the impact of the concept
of acute-on-chronic liver failure (ACLF) on the assessment of
patients with decompensated cirrhosis.
The traditional diagnostic criteria of renal failure in cirrhosis
were proposed 17 years ago [2] and have been improved in subse-
quent years: (1) it is based on the presence of a serum creatinine
over 1.5 mg/dl which represents a GFR below 40 ml/min; (2) the
cause of renal dysfunction is important in the deﬁnition (HRS,
hypovolemia, acute tubular necrosis, nephrotoxicity, infections,
chronic nephropathy); (3) HRS is divided into 2 types (type 1
and 2) according to the progression of renal failure; (4) signiﬁcant
deterioration of renal function (i.e., after therapeutic paracentesis
or diuretics) is deﬁned by an increase in serum creatinineP50% toJournal of Hepatology 20
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bacterial infections (in the absence of septic shock) may follow a
rapidly progressive (type-1 HRS), steady (type-2 HRS), and spon-
taneously reversible (transient renal failure) course [5].
This traditional classiﬁcation correlates with pathophysiolog-
ical features, therapeutic response, and prognosis. For example,
type 2 HRS is usually the extreme expression of the spontaneous
deterioration of the circulatory function that occurs in cirrhosis
as a consequence of splanchnic arterial vasodilation and impair-
ment in cardiac function. It is associated with refractory ascites
and poor survival (months) [6]. Type 1 HRS is an ARF that occurs
secondarily to a rapid deterioration of the cardiocirculatory func-
tion [7] in closed temporal relationship with bacterial infections,
acute alcoholic hepatitis, or other precipitating events, and is
associated with extremely poor survival (days or weeks). Type
1 and type 2 HRS can reverse following treatment with terlipres-
sin and albumin. However, recurrence of renal failure following
discontinuation of treatment is the rule in type 2 HRS and infre-
quent in type 1 [8]. Renal failure due to hypovolemia (i.e., diuret-
ics, diarrhoea) is moderate and usually reversible following
discontinuation of the precipitating cause [9]. Renal failure sec-
ondary to chronic nephropathy is slowly progressive and associ-
ated with better survival than type 2 HRS [9]. Finally, the severity
of renal failure associated with bacterial infection depends on the
resolution of the infection and, in cases without septic shock, on
the clinical course of renal failure [5].
AKI classiﬁcation is based on three major points: (1) renal
impairment: small increase in serum creatinine (P0.3 mg/dl or
P50% over baseline). This is the most relevant aspect of the AKI
concept. If ARF (or type-1 HRS) could be detected early by small
increments in serum creatinine, even within the normal range
(i.e., from 0.6 to 1 mg/dl), speciﬁc measures or treatments could
applied very early to prevent an evolution to more severe forms
of the syndrome; (2) time: the increase in serum creatinine should
be abrupt, within 48 hours; (3) although the Clinical Practice
Guideline for Acute Kidney Injury clearly states that etiology is
important for therapy, it is not needed for diagnosis of AKI and
staging [1].
The substitution of the traditional diagnostic criteria of renal
failure in cirrhosis for AKI requires evidence indicating advanta-
ges of one classiﬁcation over the other. However, at present such
evidence is lacking. Several studies of AKI in cirrhosis conﬁrm13 vol. 59 j 415–417
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that mortality is higher in patients with AKI than in those
without AKI and increases in parallel with AKI staging [10–12].
However, this is also the case after classifying patients on the
basis of traditional criteria and there is no comparative study
between both types of stratiﬁcation. Up to now, it was unknown
whether increments in serum creatinine P0.3 mg/dl, but below
1.5 mg/dl (the cut-off level required for diagnosis of renal failure
in the traditional concept), are associated with higher mortality
in comparison to unmodiﬁed serum creatinine or increments of
serum creatinine <0.3 mg/dl. Finally, current studies of AKI in cir-
rhosis are insufﬁciently powered or present methodological pit-
falls that limit the interpretation of data. For example, the
interval between serum creatinine measurements used to deﬁne
AKI in many of these studies ranges from days (usually more than
2) to months and this interval is not appropriate for detection of
abrupt changes in renal function [10,11].
The current issue of the Journal of Hepatology publishes two
prospective investigations on AKI in cirrhosis. The study of Fagun-
des et al. [13] includes 375 consecutive patients admitted with
acute complications. Piano et al. [14] included 233 consecutive
patients with ascites. The Piano’s study was especially strict in
the diagnostic criteria of AKI. Serum creatinine was measured at
admission (baseline) and monitored daily during hospitalization.
In both studies, patients with AKI-1 were subdivided into two
groups, those with an increase in serum creatinine P0.3 mg/dl
but without reaching 1.5 mg/dl and those in whom serum creati-
nine reached a peak over 1.5 mg/dl. Both studies showed marked
differences between patients from these two groups. In the study
of Fagundes et al., patients with AKI-1 serum creatinine 61.5
showed a 90-day probability of survival similar to that of patients
without AKI. By contrast, patients with AKI-1 serum creatinine
>1.5 showed signiﬁcantly lower 90-day probability of survival
than the previous 2 groups. In the study of Piano et al., the in-hos-
pital mortality of patients with AKI-1 was higher, although not
signiﬁcant, than that of patients without AKI. However, again pro-
gression of AKI and mortality were signiﬁcantly higher, and reso-
lution of AKI signiﬁcantly lower in patients with AKI-1 serum
creatinine P1.5 than in patients with AKI-1 serum creatinine
<1.5 mg/dl. Both studies therefore suggest that AKI-1 serum creat-
inine <1.5 mg/dl is a benign condition and that it is the progres-
sion of renal impairment to a signiﬁcant reduction of GFR
(serum creatinine >1.5 mg/dl) that determines a poor prognosis.
The recent introduction of the concept of acute-on-chronic
liver failure (ACLF) adds a new dimension to the impairment of
renal function in cirrhosis. According to the Canonic study (an
observational investigation in 1343 patients), renal failure in cir-
rhosis is not an independent complication but rather a part of a
complex syndrome, ACLF, in which the impairment in renal func-
tion occurs in the setting of an impairment in the function of
other organs (liver, cerebral, coagulation, respiration, and circula-
tion) as a consequence of an intense inﬂammatory reaction
related to bacterial infection, alcoholic liver injury, or other, as
yet, unidentiﬁed mechanisms [15]. ACLF grade 1 is deﬁned by
the presence of renal failure (creatinineP2 mg/dl) or other single
organ failures associated with renal dysfunction (serum creati-
nine 1.5–1.9 mg/dl) or moderate hepatic encephalopathy (grade
1–2), ACLF-2 by the presence of 2 organ failures, and ACLF-3 by
the presence of 3 or more organ failures. The deﬁnition of organ
failures was based on a sequential organ failure assessment
(SOFA) score speciﬁcally adapted to cirrhotic patients. The prev-
alence of ACLF at enrolment or during hospitalization was 31%416 Journal of Hepatology 201and the 28-day and 90-day mortality rates were of only 1.9%
and 9.8%, respectively, in patients without ACLF, and of 33% and
51.2% in patients with ACLF (ranging from 23.1% and 40.8% in
ACLF-1 to 74% and 78% in ACLF-3), indicating that stratiﬁcation
based on the function of the most important vital organs corre-
lates closely with short- and mid-term mortality. There are three
studies assessing AKI and other stratiﬁcation methods or scores
(Child-Pugh, MELD, APACHE II, APACHE III, SOFA) in critically ill
cirrhotic patients and they all showed SOFA as the most accurate
method in predicting short-term mortality [16–18].
In summary, with the current data, it is not possible to ascer-
tain whether the AKI classiﬁcation improves the traditional diag-
nostic criteria of renal failure in cirrhosis in terms of prediction of
morbidity and mortality. AKI-1 is associated with increased mor-
tality only in patients with signiﬁcant decrease in GFR and peak
serum creatinine >1.5 mg/dl. Stratiﬁcation of cirrhotic patients
on the basis of a single organ function (kidney, liver or brain) is
an oversimpliﬁcation of the pathophysiological features occur-
ring in patients with decompensated cirrhosis. Not surprisingly,
stratiﬁcation according to kidney function and the function of
other vital organs is the most accurate system to predict morbid-
ity and mortality in these patients.Conﬂict of interest
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